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Aims: The majority of insulin users have elevated HbA1c. There is growing recognition that the low success
rates are due to variations in insulin requirements. Thus, frequent dosage adjustments are needed. In practice,
adjustments occur sporadically due to limited provider availability. We investigated intra-individual
dynamics of insulin requirements using data from a service evaluation of the d-Nav® Insulin Guidance
Service. This service facilitates automated insulin dosage adjustments, as often as needed, to achieve and
maintain optimal glycemic balance.
Methods: Data were collected from subjects who have been using the service for more than a year. Events of
considerable and persistent decrease in insulin requirementswere identiﬁed by drops in total daily insulin ≥25%.
Results: Overall, 62 patients were studied over an average period of 2.1 ± 0.5 (mean ± standard deviation)
years. Stability in HbA1cwas attained after ~3 quarters at 7.4% ± 0.2% (57.4 mmol/mol ± 1 mmol/mol). Events
were identiﬁed in 56.5% of the patients. On average, each affected patient had 0.8 ± 0.4 events per year, lasting
9.7 ± 6.6 weeks, while total daily insulin dosage decreased by 41.4 ± 13.4%.
Conclusions:Our ﬁndingsmay call attention to amajor contributing factor to hypoglycemia among insulin users.
In reality, insulin dosage is seldom adjusted and thus transient periods of decrease in insulin requirements and
overtreatment are usually overlooked.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Insulin is one of the most commonly prescribed classes of
medications worldwide. Its main users are patients with advanced
type 2 diabetes who have become insulin deﬁcient. Despite the
long-term availability and potential advantages of insulin therapy, in
practice, its effectiveness has been disappointing. This discrepancy
between potential and practice has been called the “insulin paradox”
(Hodish, 2015). Compared to other agents used for the management
of diabetes, insulin formulations do not have upper dosage limits, they
offer diverse pharmacodynamics proﬁles and have only one source of
toxicity, namely hypoglycemia. Yet, average glycated hemoglobin
(HbA1c) among patients treated with insulin has not improved for
decades (Hoerger, Segel, Gregg, & Saaddine, 2008; Selvin, Parrinello,
Daya, & Bergenstal, 2015). Among insulin users in the USA, theutive ofﬁcer for Hygieia; Israel
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Inc. This is an open access article uaverage HbA1c is 8.5% (69.4 mmol/mol) while a third of users
continue to experience HbA1c at 9% (75 mmol/mol) or higher (Chen,
Abbott, Nguyen, Grabner, & Quimbo, 2013).
There is a growing recognition that the “insulin paradox” results
from intra-individual and inter-individual variations in insulin require-
ments. Frequent insulin dosage adjustments can overcome those
dynamics and enable maintenance of optimal glycemic control while
minimizing occurrences of hypoglycemia (Bashan, Herman, & Hodish,
2011; Davidson, 2009; Hodish, 2015; Riddle et al., 2015; Rosenthal,
Herman, WH, & Hodish, 2011). But in practice, insulin adjustments are
done sporadically during outpatient clinic visits every 3–6 months.
Intra-individual variations in insulin requirements may potentially
explain deterioration in glycemia once frequent insulin adjustments
are no longer available. If drops in insulin needs are indeed
considerable and expose patients to bouts of hypoglycemia, then
the therapy's safety is undermined. This may drive patients and
providers to lower insulin dosage, eventually causing prolonged
hyperglycemia when future insulin needs increase.
To date, HbA1c goals have been achieved and maintained
primarily in clinical trials that implement insulin dosage adjustment
every few days–weeks (Bastyr et al., 2015; Bergenstal et al., 2008;
Buse et al., 2009; Group TDCaCTR, 1993; Herman et al., 2005; Holmannder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Changes in insulin dosage and HbA1c. A) Example of a patient using basal–bolus insulin therapy for type 2 diabetes. Until 12/2013 total daily insulin was gradually increased
by d-Nav up to about 400 units per day when it plateaued for about 4 months. On 03/10/2014, insulin requirements started to decline (red cycle number 1) until reaching a nadir on
9/10/14 (red cycle number 2), at about 200 units per day. In 09/2014, insulin requirements started to rise again. HbA1c levels have remained stable from 12/2013. B) Average
changes in HbA1c before and during the d-Nav service. HbA1c stability was attained after 3 annual quarters on the d-Nav Insulin Guidance Service (DIGS). Red line denotes a moving
average with a ﬁlter of 5 quarters.
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beneﬁcial effect lasts only as long as periodic adjustments are made by
themedical staff, evidenced by deterioration of glycemic control within
a few months after the studies end and insulin titrations became more
sporadic (Hayward et al., 2015; The_writing_team_of_the_DCCT, 2002).
The goal of this study was to determine the magnitude of
intra-individual variability in insulin requirements. We have used data
from a service evaluation of the d-Nav® Insulin Guidance Service. This
service facilitates automated insulin dosage adjustments, as often as
needed, to achieve and maintain optimal glycemic balance (Bashan,
Harper, Bi, & Hodish, 2015; Donnelly & Harper, 2015). Based on
continuous analysis of glucose data, a handheld device called d-Navprovides adjustments to insulin dosage at least on a weekly basis to
achieve a consistent balance between hyperglycemia and hypoglycemia.
Drops in insulin requirements are recognized in real time and dosage is
reduced accordingly. This automated process enables identiﬁcation of
signiﬁcant decline in insulin requirements in each individual over time.
2. Materials and methods
2.1. The d-Nav insulin guidance service
The service includes a combination of diabetes nurses and
technology to improve glycemic control in patients. The service relies
Table 1
Baseline demographics and clinical characteristics.
N = 62 SD = standard deviation
Gender (number): Diabetes complications (%):
Male 33 Retinopathy 11.3
Age (years; mean ± SD): 58.1 ± 9.1 Chronic kidney disease 11.3
Race (%): Proteinuria 14.5
Caucasian 54.1 Neuropathy 17.7
Afro-Caribbean 1.6 Lower limb amputation 3.2
Not reported 43.5 Comorbidities (%):
Diabetes type; number
of patients (%):
Hypertension 79.0
Type 2 56 (90.3%) Dyslipidemia 82.2
Secondary 1 (1.6%) Coronary artery disease 37.1
Not reported 5 (8.1%) Cerebral vascular disease 9.7
Duration of diabetes
(years; mean ± SD):
12.1 ± 5.8 Smoking (current) 9.7
Duration on Insulin
(years; mean ± SD):
4.7 ± 4.1
Duration on the
d-Nav® Insulin
Guidance Service
(years; mean ± SD):
2.1 ± 0.5
BMI (kg/m2; mean ± SD): 36.6 ± 6.7
HbA1c 9.2% ± 1.4%;
77 ± 7 mmol/mol
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with an individualized insulin dose for each injection. Patients use
d-Nav to monitor glucose level before each injection. In addition to
providing the patient's glucose level, d-Nav provides a recommended
insulin dose. By analyzing glucose patterns, d-Nav automatically
adjusts insulin dosage. This enables providing patients with dynamic
insulin therapy to ﬁt their changing needs while preventing an
increase in hypoglycemia. Adjustments are typically made weekly by
the device. Yet, if insulin requirements drop or hypoglycemia ensues,
the device makes more frequent adjustments as needed. The service
nurses, periodically follow up with service subscribers via telephone
calls and in-person consultations to bestow user conﬁdence, correct
usage errors, and identify uncharacteristic clinical courses. The nurses are
not involved in theprocess of insulin dosage titration,which is handled by
d-Nav. More technical information can be found elsewhere (Bashan &
Hodish, 2012; Bashan et al., 2011, 2015; Bergenstal, Bashan, McShane,
Johnson,&Hodish, 2012;Donnelly&Harper, 2015;Rosenthal et al., 2011).
2.2. Subjects
Data were obtained from the South Eastern Health and Social Care
Trust's Ulster Hospital, Belfast, United Kingdom (Bashan et al., 2015;
Donnelly & Harper, 2015). The center referred patients who were
adult insulin users and whose HbA1c had been consistently N7.0%
(53 mmol/mol). Patients were excluded from the service if they had
experienced more than two episodes of severe hypoglycemia in the
past year; if they had a history of hypoglycemia unawareness; if they
had been using less than a total of 25 units of insulin daily; or if their
individual HbA1c goalwas different than 6.5%–7.5% (47.5–58.5 mmol/mol)
(American Diabetes A, 2014; National_Institute_for_Health_and_Clinical_
Excellence(NHS), 2011).
During the initiation visit, d-Nav was set up for each patient with
their current insulin regimen and dosage. Patients were then asked to
use d-Nav tomeasure blood glucose before every insulin injection and
label each glucose reading (e.g., “breakfast”) based on their routine
and insulin regimen, and once a week during the night. Patients were
also asked to measure their blood glucose every time they suspected
or felt symptoms of hypoglycemia to allow d-Nav to immediately
adjust insulin dosage if required, with the aim of preventing further
hypoglycemic events. Information from d-Nav on insulin dosage and
blood glucose levels was regularly downloaded during visits at the
service center and with the Ulster diabetes care team.2.3. Analysis of dynamics in insulin requirements
Data from patients whose insulin therapy was managed by the
service for more than a year were used for analysis. Total daily insulin
was calculated by adding each dosage component in the current
d-Nav regimen. For instance, a patient using 30 units of long-acting
insulin per day, plus 12 units of rapid-acting insulin for breakfast, 15
units for lunch and 8 units for dinner would be receiving 65 units of
total daily insulin. Correction factors were not incorporated in the
calculation.
Events demonstrating considerable and persistent decline in
insulin requirements were identiﬁed as follows. Every time dosage
decreased, we examined insulin dosage four weeks after the initial
drop occurred. If total daily insulin dosage was lower than the initial
drop, then a period of persistent decline in insulin dosage had started.
For instance, if on September 1st total insulin dosage dropped from
100 units/day to 92 units per day, then insulin dosage on September
28 would determine whether this drop was persistent. If 4 weeks
later the dosage was 91 units per day or less, then on September 1st a
period of dosage reduction had started.
Periods of dosage reduction ended when one of the following two
criteria was met: a) total insulin dosage was higher than at the point
where insulin began to drop (in our previous example that would be a
dosage of 101 or more units per day); or, b) a persistent period of
dosage increase had started. Once dosage was no longer declining, a
search for the minimal dosage point within the valid interval was
executed. The magnitude of the dosage decrease was deﬁned by the
ratio of the minimum dosage point to baseline dosage at the
beginning of the interval. The length was deﬁned as the total time
between the initial drop until the minimum has been reached.
A period of dosage increase was deﬁned by examining total daily
insulin dosage 13 weeks forward. If in 13 weeks, insulin dosage was
higher than at any given point, then that indicated a change of trend;
insulin dosage was now increasing, rather than decreasing. The
thirteen-week period was used as a threshold since seasonal changes
that last about 13 weeks have been suggested to affect hypoglycemic
rate (Ishii, Suzuki, Baba, Nakamura, & Watanabe, 2001).
Duration of each event of decrease in insulin requirements was
determined based on the analysis above. A cutoff of 25% dosage
reduction or higher was deemed clinically signiﬁcant based on
published guidelines (Holman et al., 2007). The analysis focused on
dosage decrease rather than increase to offer a safety dimension.
The example in Fig. 1A illustrates attenuations in total daily insulin
in a patient using basal–bolus insulin therapy. On 03/10/2014, total
daily insulin started to decline (red cycle number 1) until reaching a
nadir on 09/10/2014 (red cycle number 2). The entire period lasted for
24.3 weeks with a total dosage reduction of 51.25%.
2.4. Statistical analysis
Results are presented asmean ± standard-deviation (SD). Median
and 75th quartiles were used to illustrate distribution of event
durations, frequency and insulin dosage drop. Normality was
determined by the Shapiro–Wilk test. The Spearman Correlation test
was used to assess correlation between frequency of insulin decrease
events and patients' related parameters. Attenuations in HbA1c were
assessed for statistical signiﬁcance by the Wilcoxon matched-pairs
signed rank test. A p-value b0.05 was deﬁned as statistically
signiﬁcant.3. Results
Overall, data for 62 patients treated by the d-Nav Insulin Guidance
Service for more than a year were available for this analysis. Table 1
1336 R. Harper et al. / Journal of Diabetes and Its Complications 30 (2016) 1333–1338shows basic characteristics. Average age was 58.1 ± 9.1 (mean ±
SD) years, 56 (90.3%) had type 2 diabetes, patients had diabetes for
12.1 ± 5.8 years, and had been using insulin for 4.7 ± 4.1 years.
Initial BMI was 36.6 ± 6.7 kg/m2. Patients were enrolled in the
service for 2.1 ± 0.5 years. In average, stability inHbA1cwasattainedafter
the 3rd annual quarters at 7.4% ± 0.2% (57.4 mmol/mol ± 1 mmol/mol),
while only 4.8%of patients hadHbA1C N 8% (64 mmol/mol) (the lowest
HbA1c after the 3rd annual quarter on d-Nav) (Fig. 1B).
Events of considerable and persistent decline in insulin require-
ments (dosage drops ≥25%), were identiﬁed in 56.5% of the patients.Fig. 2. Decline in insulin requirements. A) Histogram depicting duration of decrease in insu
depicting percentage of dosage reduction in increments of 5%. In half of the cases, total da
dosage reduction per year. In half of the cases, events occurred more than 0.6 per year. D)In 67.7% of patients, dosage dropped ≥20%. In patients who did have
signiﬁcant drops in insulin requirements, each patient had 0.8 ± 0.4
events per year, of which 78.9% started after average HbA1c dropped
below 8% (64 mmol/mol). Periods lasted on average 9.7 ± 6.6 weeks
and total daily insulin dosage was decreased by 41.4 ± 13.4%.
In half of the patients with reduction in insulin dosage, duration of
events exceeded 8.4 weeks and in the 4th quartile it exceeded
13.6 weeks (Fig. 2A). In half of the patients with the events, dosage
decreased by more than 37.8% and in the 4th quartile dosage
decreased by more than 51.2% (Fig. 2B). In half of the patients withlin needs. In half of the cases, duration of the period exceeded 8.4 weeks. B) Histogram
ily insulin dosage decreased by more than 37.8%. C) Histogram depicting frequency of
Histogram depicting event occurrence as a function of time after d-Nav initiation.
Fig. 2. (continued).
1337R. Harper et al. / Journal of Diabetes and Its Complications 30 (2016) 1333–1338reduction in insulin dosage, events occurred more than 0.6 times per
year and in the 4th quartile it exceededmore then 0.9 (Fig. 2C). Events
occurred during all seasons (26% of the events occurred during the
winter, 28% during the spring, 18% during the summer and 28% during
the fall) and randomly after the initiation of the service (Fig. 2D). Once
HbA1c decreased below 8% (64 mmol/mol), there was no further
correlation between HbA1c and dosage drops (not shown). No
correlation was found between insulin dosage per body-weight per
day and dosage drops (not shown).
We examined how many of the events could have been explained
byweight loss.Weight data were available for all patients except for 4.We identiﬁed weight loss of more than 5% from the highest weight
prior to weight loss. Five percent cutoff was used based on its
potential impact on the progression of early disease (Knowler et al.,
2002). In 4 events the reduction in insulin requirement was associated
with weight loss. In the remaining 57 events of signiﬁcant reduction
in insulin requirement, no reduction in weight was observed.
4. Discussion
While the concept of frequently adjusted insulin therapy is
expanding, more data regarding the physiology/pathophysiology of
1338 R. Harper et al. / Journal of Diabetes and Its Complications 30 (2016) 1333–1338insulin requirements is coming to light as we have revealed in this
report. When patients are either insulin naïve or overtly undertreated
with insulin, the approximate ratio of insulin units required per kg
bodyweight in each patient is unknown and impossible to predict. For
instance, when a patient with advanced type 2 diabetes is being
considered for insulin therapy, the average requirement can be as high
as 2 units per kg of body weight (Bergenstal et al., 2008; Riddle et al.,
2015). In addition, inter-individual needs can vary up to 10 fold (e.g.,
somepatientsmay eventually need30units per day or less,while others
need 300 units per day or more) (Bergenstal et al., 2008; Riddle et al.,
2015). It is clear that the induction of insulin therapy is an intense
process, which is best served with frequent dosage titrations. However,
what has not been clariﬁed is thedynamic nature of insulin needs,when
target HbA1c has already been reached. This is particularly important
since hypoglycemia has been a major safety concern in insulin therapy
(Pathak et al., 2015).
In a previous work, we reanalyzed data from a clinical trial in
which a specialized study team had facilitated frequent insulin dosage
adjustment by phone calls in a group of patients with type 2 diabetes
over a period of a year. The number of components changed by the
team (e.g., breakfast rapid-acting insulin, lunchtime rapid-acting
insulin, long-acting insulin, etc.), as well as intensity of changes and
the clinical effort needed for those adjustments to maintain HbA1c
within the target was similar to the one that was needed to achieve
HbA1c goals in the ﬁrst place (Herman et al., 2005; Rosenthal et al.,
2011).
The current report sheds light as to the reason. In a majority of
patients, insulin requirements change considerably over time,
requiring substantial percentage of dosage change (Fig. 2A and B).
Insulin requirements occur in all seasons, unrelated to weight or to
HbA1c once decreased below 8% (64 mmol/mol), thus making them
difﬁcult to predict.
To our best knowledge, the reasons for these variations have not
been elucidated, although they likely include minor changes in
physical activity, diet, emotional stressors, etc. Additionally, it is likely
that availability in endogenous insulin secretion can change over time
and can potentially recover to some extent once glucotoxicity has
subsided (Chick & Like, 1970; Flax, Matthews, Levy, Coppack, &
Turner, 1991; Harper & Hodish, 2015; Kluth et al., 2011).
As we revealed in our report, events of considerable and persistent
decline in insulin needs are common. This may explain why many
patients suffer from bouts of hypoglycemia between clinic visits and
thus become subject to treatment-related anxiety and risk. It is very
likely that such episodes prompt both patients and providers to
indiscriminately lower dosage and impair glycemic control while
requirements may rise, as suggested in post-clinical trial periods
(Hayward et al., 2015; The_writing_team_of_the_DCCT, 2002).
Limitations of the study include limited sample size and lack of
multicenter data source.
Our ﬁndings may call attention to a major contributing factor to
hypoglycemia among insulin users. Insulin dosage is seldom
adjusted, so transient periods of decrease in insulin requirements
are often overlooked, leading to overtreatment. Unfortunately, many
patients are under-dosed with insulin (Bergenstal et al., 2008; Riddle
et al., 2015) and thus changes in insulin requirements are not even
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